Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-01-31
2006-01-31
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S182000, C552S618000
Reexamination Certificate
active
06992075
ABSTRACT:
The present invention relates to novel estrogenic compounds. The present invention also relates to methods of treating estrogen deprivation in a subject comprising administering novel estrogenic compounds. Additionally, the present invention relates to methods of synthesizing novel estrogenic compounds.
REFERENCES:
patent: 3230142 (1966-01-01), Spero
patent: 3487152 (1969-12-01), Carstensen et al.
patent: 3502772 (1970-03-01), Ijzerman
patent: 3568828 (1971-03-01), Lerner
patent: 3591688 (1971-07-01), Jones et al.
patent: 3639600 (1972-02-01), Hnedrix
patent: 3733407 (1973-05-01), Segre
patent: 3795734 (1974-03-01), Rochefort
patent: 3813418 (1974-05-01), Hofmeister et al.
patent: 3836651 (1974-09-01), Rudel et al.
patent: 3932635 (1976-01-01), Segre
patent: 3939264 (1976-02-01), Lachnit-Fixson
patent: 3942641 (1976-03-01), Segre
patent: 3957982 (1976-05-01), Lachnit-Fixson et al.
patent: 3969502 (1976-07-01), Lachnit-Fixson
patent: 4027019 (1977-05-01), Shroff
patent: 4066757 (1978-01-01), Pasquale
patent: 4071623 (1978-01-01), van der Vies
patent: 4145416 (1979-03-01), Lachnit-Fixson et al.
patent: 4147783 (1979-04-01), van der Vies
patent: 4154820 (1979-05-01), Simoons
patent: 4210644 (1980-07-01), Ewing et al.
patent: 4259325 (1981-03-01), Prezewowsky et al.
patent: 4291028 (1981-09-01), Vorys
patent: 4292315 (1981-09-01), Vorys
patent: 4315925 (1982-02-01), Hussain et al.
patent: 4327725 (1982-05-01), Cortese et al.
patent: 4378356 (1983-03-01), De Jager
patent: 4383993 (1983-05-01), Hussain et al.
patent: 4390531 (1983-06-01), Edgren
patent: 4425339 (1984-01-01), Pitchford
patent: 4512986 (1985-04-01), Reel et al.
patent: 4530839 (1985-07-01), Pasquale
patent: 4544554 (1985-10-01), Pasquale
patent: 4616006 (1986-10-01), Pasquale
patent: 4621079 (1986-11-01), Lachnit-Fixson et al.
patent: 4628051 (1986-12-01), Pasquale
patent: 4738957 (1988-04-01), Laurent et al.
patent: 4756907 (1988-07-01), Beck et al.
patent: 4762717 (1988-08-01), Crowley, Jr.
patent: 4764378 (1988-08-01), Keith et al.
patent: 4783337 (1988-11-01), Wong et al.
patent: 4816257 (1989-03-01), Buster et al.
patent: 4816258 (1989-03-01), Nedberge et al.
patent: 4826831 (1989-05-01), Plunkett et al.
patent: 4855305 (1989-08-01), Cohen
patent: 4900734 (1990-02-01), Maxson et al.
patent: 4914089 (1990-04-01), Tax
patent: 4921843 (1990-05-01), Pasquale
patent: 4962098 (1990-10-01), Boissonneault
patent: 4977147 (1990-12-01), Jungblut et al.
patent: 5006345 (1991-04-01), Lang
patent: 5010070 (1991-04-01), Boissonneault
patent: 5043331 (1991-08-01), Hirvonen et al.
patent: 5089482 (1992-02-01), Hermens et al.
patent: 5098714 (1992-03-01), Wright et al.
patent: 5108995 (1992-04-01), Casper
patent: 5130137 (1992-07-01), Crowley, Jr.
patent: 5183814 (1993-02-01), Dukes
patent: 5200197 (1993-04-01), Wright et al.
patent: 5208225 (1993-05-01), Boissonneault et al.
patent: 5210081 (1993-05-01), Raveendranath et al.
patent: 5262408 (1993-11-01), Bergink
patent: 5276022 (1994-01-01), Casper
patent: 5280023 (1994-01-01), Ehrlich et al.
patent: 5288717 (1994-02-01), Raveendranath et al.
patent: 5362720 (1994-11-01), Labrie
patent: 5382573 (1995-01-01), Casper
patent: 5418228 (1995-05-01), Bennink
patent: 5434146 (1995-07-01), Labrie et al.
patent: 5464871 (1995-11-01), Kun et al.
patent: 5510342 (1996-04-01), Washburn et al.
patent: 5541172 (1996-07-01), Labrie et al.
patent: 5545634 (1996-08-01), Labrie
patent: 5547948 (1996-08-01), Barcomb
patent: 5567695 (1996-10-01), Labrie
patent: 5629303 (1997-05-01), Labrie et al.
patent: 5654011 (1997-08-01), Jackson et al.
patent: 5753639 (1998-05-01), Labrie
patent: 5759576 (1998-06-01), Barcomb
patent: 5759577 (1998-06-01), Barcomb
patent: 5807586 (1998-09-01), Jackson et al.
patent: 5846960 (1998-12-01), Labrie
patent: 5861387 (1999-01-01), Labrie et al.
patent: 5861431 (1999-01-01), Hildebrand et al.
patent: 5908638 (1999-06-01), Huber et al.
patent: RE36247 (1999-07-01), Plunkett et al.
patent: 5998639 (1999-12-01), Raijmakers et al.
patent: 6040333 (2000-03-01), Jackson
Andreolini, et al.,Estrogen Conjugates in Late-Pregnancy Fluids: Extraction and Group Separation by a Graphitized Carbon Black Cartridge and Quantification by High-Performance Liquid Chromatography, Anal. Chem. 59:1720-1725 (1987).
Center for Drug Evaluation and Research (CDER),Guidance for Industry, Draft Guidance,Conjugated Estrogens. USP—LC-MS Method for Both Qualitative Chemical Characterization and Documentation of Qualitative Pharmaceutical Equivalence, Mar. 2000, <http://www.fda.gov/cder/guidance/index.htm>.
Conjugated Estrogens. The United States Pharmacopeia (USP), published by United States Pharmacopeial Convention, Inc., pp. 627-629 (2000).
FDA Backgrounder on Conjugated Estrogens, May 5, 1997, <http://www.fda.gov/cder/cebackground.htm>.
FDA Statement on generic Premarin, HHS News Press Release, P97-12, May 5, 1997, <http://www.fda.gov/cder/cepressrelease.htm>.
Fujino, et al.,3-(Difluoro-1,3,5-trianinyl)-1-(ethylthio)-2-n-propylbenz[f]isoindole as a Fluorescence Derivation Reagent for Estrogens in High-Performance Liquid Chromatography, Chem. Pharm. Bull., 37(7): 1939-1940 (1989).
International Search Report corresponding to PCT/US 01/07544; mailed on Aug. 6, 2001.
Ishida, et al.,Determination of Oestrogens in Pregnancy Urine by High-Performance Liquid Chromatography with Fluorescence Detection, Journal of Chromatography, 431: 249-257 (1988).
Letter from Yana Ruth Mille, Chief, Compendial Operations Staff, HFD-354, Office of Pharmaceutical Science, Center for Drug Evaluation & Research to Joseph G. Valentino, J.D., Senior Vice President and General Counsel, The United States Pharmacopeial Convention, Inc. (Mar. 8, 2000) (REF: 3-00-001-O).
Letter from Yana Ruth Mille, Chief, Compendial Operations Staff, HFD-354, Office of Pharmaceutical Science, Center for Drug Evaluation & Research to Joseph G. Valentino, J.D., Senior Vice President and General Counsel, The United States Pharmacopeial Convention, Inc. (Mar. 8, 2000) (REF: 3-00-002-O).
Memorandum from Janet Woodcock, M.D., Director, Center for Drug Evaluation & Research to Douglas L. Sporn, Director, Office of Generic Drugs, regarding Approvability of a Synthetic Generic Version of Premarin (May 5, 1997).
NDA 20-992 Cenestin™ (synthetic conjugated estrogens, A) Tablets Physicians Package Insert, pp. 1-10 (1999).
NDA 20-992 Cenestin™ (synthetic conjugated estrogens, A) Tablets Patient Package Insert, pp. 11-13 (1999).
New Drug Approval for Cenestin, Synthetic Conjugated Estrogens, A: Mar. 24, 1999,Questions and Answers, <http://www.fda.gov/cder
ews/cenestin/qa.htm>.
Novakovic, et al.,High-Performance Liquid Chromatographic Dtermination of Equine Estrogens with Ultraviolet Absorbance and Electrochemical Detection, Journal of Chromatography A, 678: 359-363 (1994).
Physician's Desk Reference, 53: 3367-3379 (1999).
Rzheznikov, V. M. et al., “Synthesis and Biological Activity of Estrone 8-iso- and D-homoanalogs Oxidized for Rings B and C,”Database Chemabs 'Online!, Journal of Chromatography A, 678: 359-363 (1994).
Sakac, Marija N. et al., “Synthesis of New Steroidal N-butyl-N-methyl-undecanamide Derivatives,”Database Chemabs 'Online!, Database accession No. 133:335378 XP002171995, Zb. Matice Srp. Prir. Nauke 96: 5-9 (1999).
Sakac, Marijan N. et al., “Chemical Behavior of 3, 17.beta.-dipropionoxy-9.alpha.-hydroxyestra-1,3,5(10)-trien-6-one,”Database Chemabs 'Online!, Database accession No. 128:180573 XP002171996, J. Serb. Chem. Soc., 63(1): 21-24 (1998).
Synthetic Generic Conjugated Estrogens: Timeline, May 5, 1997, <http://www.fda.gov/cder
ews/cetimeline.htm>.
Takadate, et al.,A Convenient Derivatization with Anion Exchange Resin Catalysts for High-Performance Liquid Chromatographic Analysis. I. Derivatization of Estrogens with Dansyl Chloride, Chem. Pharm. Bull., 33(11): 5092-5095 (1985).
Townsend, et al.,High-Performance Liquid Chromatographic Determination of Conjugated Estrogens in Tablets, Journal Chromatography, 450: 414
Hill Edward N.
Leonard Thomas W.
Whittle Robert R.
Badio Barbara P.
Barr Laboratories, Inc.
Myers Bigel & Sibley & Sajovec
LandOfFree
C(14) estrogenic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C(14) estrogenic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C(14) estrogenic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3571864